1. External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Thomas M. Pisansky, MD 
Mayo Clinic Proceedings 
Volume 80, Issue 7, Pages (July 2005)
DOI: /
Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

2. FIGURE 1
Nomogram for predicting the probability of prostate cancer metastasis after external beam radiotherapy based on prognostic factors. From Kattan et al.12 Reprinted with permission from the American Society of Clinical Oncology.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

3. FIGURE 2
Results of treatment for patients with at least 1 unfavorable prognostic factor (T2b-T2c, Gleason score =7, or prostate-specific antigen >10 ng/mL) according to therapeutic modality and radiotherapy (RT) dose level. RP = radical prostatectomy. From Kupelian et al.16 Reprinted with permission from the American Society of Clinical Oncology.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

4. FIGURE 3
Prostate cancer-specific mortality after external beam radiotherapy in 2370 patients with localized prostate cancer according to low-risk (T1c-T2a, Gleason score =6, or prostate-specific antigen [PSA] =10 ng/mL), intermediate-risk (T2b, Gleason score 7, or PSA ng/mL), and high-risk (T2c, Gleason scores 8-10, or PSA >20 ng/mL) groups; differences between groups were significant. From D'Amico et al.36 Reprinted with permission from the American Society of Clinical Oncology.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

5. FIGURE 4
Overall survival (4839 patients) and cause-specific survival (3547 patients) after external beam radiotherapy in patients with localized prostate cancer (left) and cause-specific survival (right) according to low-risk (T1b-T2a, Gleason score =6, and prostate-specific antigen [PSA] =10 ng/mL), intermediate-risk ([T1b-T2a, Gleason score =7, or PSA >10 but =20 ng/mL] or [T2b-T2c, Gleason score =7, or PSA =20 ng/mL]), and high-risk (Gleason scores 8-10 or PSA >20 ng/mL) groups.39
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

6. FIGURE 5
Quality of life among patients more than 1 year after undergoing external beam radiotherapy (RT) (147 patients), brachytherapy (84), or prostatectomy (671) for prostate cancer or among controls (112) without prostate cancer. Raw values represent the mean of the treatment group, with higher values indicating better quality of life. The difference between brachytherapy and controls was significant only in the prostate cancer-related domain; no other significant differences were identified. Data from Wei et al.55
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

7. FIGURE 6
Quality-of-life uniscale symptom scores before and at 3, 12, and 24 months after external beam radiotherapy in 182 patients with localized prostate cancer. Values represent the mean of the group on a scale of 0 (minimal) to 100 (maximum); higher values represent greater symptom bother. From Talcott et al.60 Reprinted with permission from the American Society of Cinical Oncology.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

8. FIGURE 7
Results of treatment for patients with at least 1 unfavorable histopathologic factor (involved surgical margin, extraprostatic extension, seminal vesicle invasion) after prostatectomy. RT = radiotherapy. From Urol Clin North Am,92 with permission from Elsevier.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions

9. FIGURE 8
Progression-free probability 4 years after external beam radiotherapy (RT) among patients treated for postoperative biochemical relapse. ADT = androgen deprivation therapy; PFP = progression-free probability; PSA = prostate-specific antigen; PSADT = PSA doubling time. Values in parentheses are 95% confidence intervals. From JAMA,100 with permission.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2005 Mayo Foundation for Medical Education and Research Terms and Conditions